Hemostemix Inc.
HEM
Kedudukan dalam Saham
#32860
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Harga Saham
$0.04036653
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$8.54M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-44.48%
Negara
CA
Perdagangan Hemostemix Inc. (HEM)
Kategori
Healthcare
Sejarah pecahan saham untuk Hemostemix Inc. (HEM)
Saham Hemostemix Inc. (simbol: HEM) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham HEM yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham HEM.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham HEM yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham HEM.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
